Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zanotti, R.
Right arrow Articles by Pizzolo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanotti, R.
Right arrow Articles by Pizzolo, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1908-1914, 2002
© 2002 European Society for Medical Oncology

Original Paper

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin’s lymphoma

R. Zanotti+, A. Trolese, A. Ambrosetti, G. Nadali, C. Visco, M. M. Ricetti, F. Benedetti and G. Pizzolo

Department of Clinical and Experimental Medicine, Section of Hematology, University of Verona, Policlinico ‘G.B. Rossi’, Verona, Italy

Received 4 February 2002; revised 3 June 2002; accepted 8 July 2002

Background:

The International Prognostic Score (IPS) and circulating levels of the soluble form of CD30 molecule (sCD30) have both been associated with poor outcome in patients with advanced Hodgkin’s lymphoma (HL). The aim of this study was to assess the prognostic power of the combined evaluation of sCD30 and IPS in these patients.

Patients and methods:

We included 101 patients with advanced HL, treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or MOPP (mechlorethamine, vincristine, procarbazine and prednisone)/ABVD chemotherapy with or without radiotherapy. All were tested for pre-treatment sCD30 levels.

Results:

Six-year estimated overall survival (OS) and failure-free survival (FFS) was 89% ± 3% and 75% ± 4%, respectively. Thirty-three patients (33%) had IPS >2; their FFS was 60% compared with 82% in the remaining patients (P = 0.027). Serum sCD30 levels were >=100 U/ml in 41 (41%) patients; their FFS at 6 years was 58%, compared with 87% in patients with sCD30 <100 U/ml (P = 0.003). In the 18 patients with both sCD30 >=100 U/ml and IPS >2, FFS was significantly worse (44%) than in patients with low sCD30 and low IPS (89%) (P <0.001) or with only one of the two adverse prognostic factors (73%) (P = 0.03).

Conclusions:

In our study, the combination of IPS >2 and serum sCD30 levels >=100 U/ml identifies a sizeable subgroup (18%) of advanced HL patients with very poor FFS, who might take advantage of intensified up-front treatment strategies.

Key words: Hodgkin’s lymphoma, International Prognostic Score, prognosis, sCD30


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
K. Matsushita, I. Margulies, M. Onda, S. Nagata, M. Stetler-Stevenson, and R. J. Kreitman
Soluble CD22 as a tumor marker for hairy cell leukemia
Blood, September 15, 2008; 112(6): 2272 - 2277.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al.
CD30 supports lung inflammation
Int. Immunol., February 1, 2008; 20(2): 177 - 184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al.
HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma
J. Clin. Oncol., July 20, 2007; 25(21): 3101 - 3108.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R.-O. Casasnovas, N. Mounier, P. Brice, M. Divine, F. Morschhauser, J. Gabarre, J.-Y. Blay, L. Voillat, P. Lederlin, A. Stamatoullas, et al.
Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., May 1, 2007; 25(13): 1732 - 1740.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Klimm, T. Reineke, H. Haverkamp, K. Behringer, H. T. Eich, A. Josting, B. Pfistner, V. Diehl, and A. Engert
Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group
J. Clin. Oncol., November 1, 2005; 23(31): 8003 - 8011.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.